Hepalink USA buys Cytovance Biologics for $205.68 mln

Hepalink USA Inc. has acquired Cytovance Biologics Inc., a portfolio company of Great Point Partners, for $205.68 million in cash. Oklahoma City-based Cytovance makes protein and antibody drugs for biotechnology and pharmaceutical companies.

ByLuisa Beltran

7 October 2015•3 mins read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.

North America US M&A Deals Briefs

Hepalink USA buys Cytovance Biologics for $205.68 mln

Great Point Partners

Shenzhen Hepalink Pharmaceutical